8-K: Neurocrine Biosciences Reports Strong Q2 2024 Results and Raises INGREZZA Sales Guidance

Neurocrine Biosciences announced positive second quarter 2024 financial results, highlighted by a 32% year-over-year growth in INGREZZA sales, and raised its full-year sales guidance for the drug.

Summary

• Neurocrine Biosciences reported its financial results for the second quarter of 2024, ending June 30, 2024.
• The company's net product sales for INGREZZA reached $580 million, a 32% increase compared to the same quarter in 2023.
• Total revenue for the quarter was $590.2 million, up from $452.7 million in the prior year.
• GAAP net income was $65 million, or $0.63 per diluted share, compared to $95 million, or $0.95 per diluted share, in Q2 2023.
• Non-GAAP net income was $169 million, or $1.63 per diluted share, compared to $126 million, or $1.25 per diluted share, in Q2 2023.
• The company raised its 2024 net product sales guidance for INGREZZA to between $2.25 billion and $2.3 billion.
• Neurocrine had approximately $1.7 billion in cash, cash equivalents, and marketable securities as of June 30, 2024.
• The company settled its convertible senior notes due May 15, 2024, in full for $309 million.
• The company is expanding its INGREZZA sales teams and building its endocrinology team.
• Top-line Phase 2 data readouts for NBI-568 and Luvadaxistat are still expected in Q3 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong sales growth, raised guidance, and pipeline advancements. While there are some negative points, the overall tone is optimistic and forward-looking.

Positives

• INGREZZA sales showed strong growth, increasing by 32% year-over-year.
• The company raised its full-year sales guidance for INGREZZA, indicating confidence in future performance.
• Neurocrine has a strong cash position of approximately $1.7 billion.
• The FDA granted Priority Review for crinecerfont, potentially accelerating its approval.
• Positive topline data from the Phase 2 SAVITRI study for NBI-1065845 is a positive development for the pipeline.
• The company is expanding its sales teams and building its endocrinology team, positioning it for future growth.
• The company successfully settled its convertible senior notes, reducing debt.
• The company has a robust pipeline with multiple compounds in midto late-phase clinical development.

Negatives

• GAAP net income decreased to $65 million in Q2 2024 from $95 million in Q2 2023.
• GAAP earnings per share decreased to $0.63 in Q2 2024 from $0.95 in Q2 2023.
• The company incurred a $50 million charge associated with the settlement of convertible senior notes conversions.
• The company experienced a $20 million loss from changes in fair value of equity security investments compared to a $37 million gain in the same quarter last year.
• The company had $14 million in impairment charges associated with leased office space.

Risks

• The company's future financial performance is subject to risks and uncertainties.
• The commercialization of INGREZZA carries inherent risks.
• There is a risk that the crinecerfont NDAs may not obtain regulatory approval or may be delayed.
• The development of product candidates is subject to risks.
• The company is dependent on third parties for development, manufacturing, and commercialization activities.
• Clinical development activities may not be successful or may be delayed.
• The company faces competition from other therapies and products.
• Government and third-party regulatory efforts may impose sales and pharmaceutical pricing controls.

Future Outlook

Neurocrine Biosciences raised its 2024 net product sales guidance for INGREZZA to $2.25 $2.3 billion and anticipates continued growth, driven by INGREZZA and the development of its pipeline. The company expects top-line Phase 2 data readouts for NBI-568 and Luvadaxistat in Q3 2024 and is planning to initiate Phase 3 studies for NBI-1065845 in 2025.

Management Comments

• Kevin Gorman stated that the company is energized by the opportunity to help more patients and is encouraged by recent progress, including INGREZZA's success and the FDA's Priority Review for crinecerfont.
• Kevin Gorman expressed confidence in Neurocrine's future as he looks ahead to his retirement.
• Kevin Gorman is proud of the company's achievements and excited for the team's future accomplishments under Kyle Gano's leadership.

Industry Context

This announcement reflects the ongoing growth in the neuroscience and biopharmaceutical sectors, with a focus on treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The success of INGREZZA and the progress of the pipeline position Neurocrine as a key player in this space. The company's focus on expanding its sales teams and building its endocrinology team aligns with the industry trend of investing in commercial infrastructure to support product launches and growth.

Comparison to Industry Standards

• Neurocrine's 32% year-over-year growth in INGREZZA sales is strong compared to the average growth rates of established pharmaceutical products.
• The company's raised sales guidance for INGREZZA to $2.25 $2.3 billion indicates a positive outlook, which is a key metric for investors in the biotech sector.
• The FDA's Priority Review for crinecerfont is a significant milestone, comparable to other companies receiving expedited reviews for promising drug candidates.
• The company's investment in R&D, including muscarinic compounds and gene therapy programs, is in line with industry trends of exploring novel therapeutic approaches.
• Neurocrine's cash position of $1.7 billion is robust, providing financial flexibility for future growth and acquisitions, similar to other well-capitalized biotech companies such as Vertex Pharmaceuticals and Regeneron.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong sales growth and raised guidance.
• Employees may benefit from the company's expansion and growth.
• Patients may benefit from the continued development of new treatments.
• Suppliers and partners may see increased business opportunities.
• Creditors may view the company's strong cash position favorably.

Next Steps

• The company will continue to expand its INGREZZA sales teams and build its endocrinology team.
• Top-line Phase 2 data readouts for NBI-568 and Luvadaxistat are expected in Q3 2024.
• The company plans to initiate Phase 3 studies for NBI-1065845 in 2025.
• The company will continue to advance its clinical pipeline, including ongoing Phase 2 and Phase 1 studies.
• The company will work towards the PDUFA target action dates for crinecerfont in December 2024.

Key Dates

Keywords

INGREZZA, Neurocrine Biosciences, tardive dyskinesia, Huntingtons disease, crinecerfont, congenital adrenal hyperplasia, NBI-1065845, major depressive disorder, clinical trials, pharmaceutical, biotechnology, sales guidance, financial results